The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 15, 2022

Filed:

Dec. 18, 2017
Applicants:

International Aids Vaccine Initiative, New York, NY (US);

The Scripps Research Institute, La Jolla, CA (US);

Inventors:

William Schief, La Jolla, CA (US);

Sergey Menis, New York, NY (US);

Daniel Kulp, New York, NY (US);

Joseph Jardine, La Jolla, CA (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01); A61K 38/00 (2006.01); A61K 39/395 (2006.01); C07K 14/005 (2006.01); A01K 67/027 (2006.01); A61K 39/12 (2006.01); A61K 39/21 (2006.01); A61K 49/00 (2006.01); C12N 7/00 (2006.01); C12N 9/10 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A01K 67/0278 (2013.01); A61K 39/12 (2013.01); A61K 39/21 (2013.01); A61K 49/0008 (2013.01); C12N 7/00 (2013.01); C12N 9/1085 (2013.01); C12Y 205/01078 (2013.01); A01K 2207/15 (2013.01); A01K 2217/072 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01); C07K 2319/00 (2013.01); C07K 2319/21 (2013.01); C12N 2740/16122 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16171 (2013.01);
Abstract

The present invention relates to engineered outer domain (eOD) immunogens of HIV gp120 and mutants thereof and methods of making and using the same. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity. The mutant eODs bind to neutralizing antibody precursors. The mutant eODs can activate germline precursors on the pathway to eliciting a broadly neutralizing antibody (bnAb) response. The invention also relates to immunized knock-in mice expressing germline-reverted heavy chains. Induced antibodies showed characteristics of bnAbs and mutations that favored binding to near-native HIV-1 gp120 constructs. In contrast, native-like immunogens failed to activate precursors. The invention also relates to rational epitope design that can prime rare B cell precursors for affinity maturation to desired targets.


Find Patent Forward Citations

Loading…